Biogen (BIIB) Total Non-Current Liabilities (2009 - 2026)

Biogen's Total Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $10.0 billion for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 2.51% year-over-year to $10.0 billion; the TTM figure through Mar 2026 stood at $10.0 billion (down 2.51% YoY), while the FY2025 annual figure was $10.4 billion, down 1.57% from the prior year.
• Total Non-Current Liabilities was $10.0 billion for Q1 2026 at Biogen, down from $10.4 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $13.0 billion in Q3 2023 to a low of $9.9 billion in Q1 2023.
• Historically, Total Non-Current Liabilities has averaged $10.7 billion across 5 years, with a median of $10.4 billion in 2025.
• Biggest YoY gain for Total Non-Current Liabilities was 19.07% in 2023; the steepest drop was 17.68% in 2023.
• A 5-year view of Total Non-Current Liabilities shows it stood at $10.2 billion in 2022, then advanced by 10.2% to $11.3 billion in 2023, then fell by 5.89% to $10.6 billion in 2024, then declined by 1.57% to $10.4 billion in 2025, then slipped by 3.74% to $10.0 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $10.0 billion (Q1 2026), $10.4 billion (Q4 2025), and $10.2 billion (Q3 2025), per Business Quant data.